Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients ...
Zacks Investment Research on MSN
NTRA & Aveta partner to advance MRD-guided trial in head & neck cancer
Natera NTRA recently announced a partnership with Aveta Biomics to support AVTA 30-01, a global Phase 3 registrational trial ...
Quest Diagnostics (NYSE:DGX) received New York State approval for its Haystack MRD liquid biopsy test, enabling nationwide ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National ...
GlobalData on MSN
Quest Diagnostics’ Haystack MRD test secures NYSDOH approval
The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour ...
Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual ...
(RTTNews) - Johnson & Johnson (JNJ) announced data highlighting that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) ...
Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack ...
Conversion from MRD negativity to positivity during maintenance is substantially lower with the quadruplet, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results